Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat plus Azacitidine in HR-MDS, CMML, and Low-Blast AML
NCT02610777Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Apr 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of pevonedistat in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Overall Survival. Started Apr 2016; status: completed.
02
Drugs
pevonedistat
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02610777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02610777.